About Ajax and our focus on hematologic malignancies Advances in molecular genetics and biology have led to the development of new classes of targeted therapies for the treatment of hematologic malignancies. However, many of these therapies, while selective for a particular drug target, often interact with other related proteins which can limit their efficacy and […]
Employees: 1-10
Total raised: $40M
Founded date: 2019
Investors 1
| Date | Name | Website |
| - | EcoR1 Capi... | ecor1cap.c... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 01.06.2021 | - | $40M | - | finsmes.co... |
Mentions in press and media 5
| Date | Title | Description | Source |
| 02.06.2021 | SoFi flies in SPAC-tacular Nasdaq debut | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign ... | fortune.co... |
| 02.06.2021 | SoFi flies in SPAC-tacular Nasdaq debut | Good morning, all. This is Fortune finance reporter Rey Mashayekhi, filling in again for Lucinda. T... | fortune.co... |
| 01.06.2021 | Ajax Therapeutics, Inc. announced that it has received $40 m... | On June 1, 2021, Ajax Therapeutics, Inc. closed the transaction. The company received $40,000,000 in... | marketscre... |
| 01.06.2021 | Ajax Therapeutics Raises $40 Million Financing To Develop No... | Ajax Therapeutics, Inc., a biotechnology company applying computational chemistry and structure-base... | marketscre... |
| 01.06.2021 | Ajax Therapeutics Raises $40M in Financing | Ajax Therapeutics, Inc., a NYC-based biotechnology company applying computational chemistry and stru... | finsmes.co... |